Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD)
Authors not listed
Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH · 2010
Abstract
This clinical trial investigates the impact of intravitreal injection of Ranibizumab antibody on the acuteness of vision. Patients included are suffering from choroidal neo-vascularization (CNV) as a consequence of age-related macular degeneration (AMD).
Initially, all patients get injections of 0.5 mg Ranibizumab in monthly intervals for 3 months. Subsequently, one group gets Ranibizumab in intervals of 2 months, whereas a second group is treated on demand.
The primary end point of the study is the change of best-corrected visual acuity after 12 month.
Secondary end points include the impact of Ranibizumab on morphological changes of the retina, the number of patients with gain or loss of 15 or more letters visual acuity after 12 months, changes in quality of life and the number of injections required during the first 12 months of treatment.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-15 MST
Cite this
APA
Anonymous. (2010). Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD). <em>Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH</em>. https://clinicaltrials.gov/study/NCT01831947
Vancouver
Anonymous. Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD). Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH. 2010.
BibTeX
@misc{anon2010Effica,
title = {Efficacy of Ranibizumab Treatment Every 2 Month Compared to Treatment on Demand on Patients With Choroidal Neo-vascularization (CNV) as a Consequence of Age-related Macular Degeneration (AMD)},
author = {Anonymous},
journal = {Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH},
year = {2010},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Vastra Gotaland Region 2020
Open access · US-GOV
The Sahlgrenska Anti-VEGF (SAHLVE) Study - a Prospective Randomized Double-blind Comparison of Bevacizumab and Aflibercept in Patients With Neovascular Age-related Macular Degeneration
New England Journal of Medicine 2006
Open access · OA
Ranibizumab for Neovascular Age-Related Macular Degeneration
University of California, San Diego 2011
Open access · US-GOV
Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab (COMPASS)
Control Delivery Systems 2001
Open access · US-GOV
A Study to Evaluate Retisert in the Treatment of Patients With the "Wet" Form of Age-Related Macular Degeneration
Bayer 2017
Open access · US-GOV
An Observational Study to Assess the Use of Intravitreal Aflibercept Injections in a Routine "Treat and Extend" Regimen in Treatment-naïve Patients Diagnosed With Wet Age-related Macular Degeneration
Oraya Therapeutics, Inc. 2012
Open access · US-GOV